Litcius/Paper detail

Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial

Huabin Hu, Liang Kang, Jianwei Zhang, Zehua Wu, Hui Wang, Meijin Huang, Ping Lan, Xiaojian Wu, Chao Wang, Wuteng Cao, Jiancong Hu, Yan Huang, Liang Huang, Huaiming Wang, Lishuo Shi, Yue Cai, Cailu Shen, Jiayu Ling, Xiaoyu Xie, Yonghua Cai, Xiaowen He, Ruoxu Dou, Jiaming Zhou, Tenghui Ma, Xingwei Zhang, Shuangling Luo, Weihao Deng, Li Ling, Hao Liu, Yanhong Deng

2021˜The œLancet. Gastroenterology & hepatology297 citationsDOI

Topics & Concepts

Microsatellite instabilityMedicineCelecoxibColorectal cancerClinical endpointInternal medicineOncologyBlockadeCancerGastroenterologyClinical trialMicrosatelliteBiologyBiochemistryAlleleReceptorGeneCancer Immunotherapy and BiomarkersInflammatory mediators and NSAID effectsCancer, Stress, Anesthesia, and Immune Response
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial | Litcius